Search the Newsreel

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

ProQR Therapeutics announced the first human validation of its RNA-editing platform for liver disease, showing dose-dependent target engagement for its AX-0810 candidate. The treatment, aimed at cholestatic liver diseases like pediatric biliary atresia, demonstrated no serious adverse events and increased plasma bile acids. ProQR …

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow (NASDAQ:PRQR) 2026-09-30

ProQR Therapeutics N.V. (PRQR) released a slide deck for a shareholder/analyst call held on September 30, 2026. The article highlights that the content was published in conjunction with this event and was prepared by Seeking Alpha's transcripts team.

HC Wainwright Cuts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $8.00

HC Wainwright has lowered its price target for ProQR Therapeutics (NASDAQ:PRQR) to $8.00 while maintaining a "buy" rating, indicating a potential upside of 381.93%. Other analysts have also issued reports on the biopharmaceutical company, resulting in an average rating of "Moderate Buy" and an …

ProQR Therapeutics' (PRQR) "Buy" Rating Reiterated at Chardan Capital

Chardan Capital has reiterated its "buy" rating for ProQR Therapeutics (NASDAQ:PRQR), setting a $3.00 price target that suggests an 80.72% upside. Other analysts have also issued ratings, contributing to an average "Moderate Buy" rating and an average target price of $7.60 for the biopharmaceutical …

H.C. Wainwright cuts ProQR stock price target on execution risks By Investing.com

H.C. Wainwright has reduced its price target for ProQR Therapeutics N.V. (NASDAQ:PRQR) to $8.00 from $12.00, citing execution and regulatory risks, despite maintaining a Buy rating. The biotech company, currently trading at $1.66, is burning through cash but holds more cash than debt and …

ProQR Therapeutics NV Investor and Analyst Event: NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing Call Transcript

This document is a call transcript from a ProQR Therapeutics NV Investor and Analyst Event focusing on NTCP modulation in biliary atresia through liver-targeted RNA editing. The event includes a formal presentation and a Q&A session, with an emphasis on forward-looking statements and associated …

Price to sales forward of ProQR Therapeutics N.V. – DUS:0PQ

The article focuses on the "Price to sales forward" financial metric for ProQR Therapeutics N.V. (DUS:0PQ), listed on the Dusseldorf Stock Exchange. It appears to be a financial data snippet or a specific page from a financial analysis platform like TradingView, showing a value …

Hugging Face co-founder joins ProQR (PRQR) to drive AI drug discovery

ProQR Therapeutics N.V. (PRQR) has appointed Chris Hart, PhD, as Chief Data and AI Officer and welcomed Thomas Wolf, PhD, co-founder of Hugging Face, as a strategic AI advisor to its Board. These appointments aim to integrate AI further into the company's drug discovery …

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

ProQR Therapeutics has appointed Chris Hart, PhD, as Chief Data and AI Officer and Thomas Wolf, PhD, co-founder of Hugging Face, as a strategic AI advisor to its Board of Directors. These appointments aim to advance ProQR's AI-enabled RNA editing drug discovery and development, …

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Brokerages

ProQR Therapeutics (NASDAQ:PRQR) has received an average "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $7.50, significantly higher than its current $1.90 opening price. The company surpassed quarterly earnings estimates, reporting a negative EPS of $0.09 against an expected …

ProQR Therapeutics (Nasdaq:PRQR) - Stock Analysis

ProQR Therapeutics Initiates AX-0811 Clinical Trial Following First Participant Dosing

ProQR Therapeutics has commenced its AX-0811 early-phase clinical trial by administering the RNA editing treatment candidate to the first participant. This study, focusing on NTCP modulation for cholestatic liver diseases like biliary atresia, will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic biomarkers. Preliminary target-engagement results …

ProQR doses first participant in AX-0811 phase 1 trial

ProQR Therapeutics N.V. (NASDAQ:PRQR) has dosed the first participant in its Phase 1 clinical trial of AX-0811. AX-0811 is an investigational RNA editing oligonucleotide designed to treat cholestatic liver diseases, including biliary atresia, and has shown improved potency and longer half-life in preclinical data …

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Should You Sell?

ProQR Therapeutics (NASDAQ:PRQR) shares have surpassed their 50-day moving average, reaching $2.11 and closing at $2.05, exceeding the average of $1.92. The company reported better-than-expected quarterly results, with a smaller adjusted loss per share and higher revenue than projected. Analysts maintain a "Moderate Buy" …

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

ProQR Therapeutics N.V. has announced that the first participant has been dosed in a Phase 1 clinical trial for AX-0811, an AI-discovered RNA editing oligonucleotide designed for cholestatic liver diseases. The company also plans to host a virtual Investor and Analyst educational event on …

ProQR to Participate in Upcoming Investor Conferences in September 2026

ProQR Therapeutics N.V. announced its participation in two upcoming investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference. Management will hold one-on-one meetings and a fireside chat to discuss the company's proprietary ADAR-mediated Axiomer™ RNA …

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month price target of $7.50. The company recently reported better-than-expected quarterly earnings and revenue. Insiders and institutional investors have shown significant buying activity in the stock.

ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Above 50-Day Moving Average - What's Next?

ProQR Therapeutics (NASDAQ:PRQR) saw its share price cross above its 50-day moving average, trading at $2.32 compared to the average of $1.87. This comes amidst positive analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $7.50, and better-than-expected quarterly …

Certain Warrants of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026.

Certain warrants of ProQR Therapeutics N.V. are currently under a lock-up agreement, which began on June 25, 2026, and is set to expire on August 24, 2026. During this period, officers and directors are restricted from directly or indirectly selling, pledging, or otherwise disposing …

ProQR Therapeutics starts with Buy rating on strong RNA editing data and upcoming clinical milestones.

ProQR Therapeutics has received a Buy rating due to promising phase 1 results for its AX-0810 drug, showing an 8-fold increase in serum bile acids, which suggests potential for treating biliary atresia. The company anticipates several key clinical milestones by early 2027, including full …

ProQR Therapeutics BV (NASDAQ: PRQR) Share Price, PRQR Stock News, PRQR Share Price & Updates

ProQR Therapeutics initiated with a Buy at BofA

Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ

The article focuses on the "Price to sales forward" financial metric for ProQR Therapeutics N.V., traded on the Frankfurt Stock Exchange under the symbol 0PQ. It appears to be a stub or a section from a larger financial data platform, providing a heading for …

PRQR Looks 1.8% Undervalued on GF Value™ at $2.45

Bank of America Securities initiated coverage on ProQR Therapeutics NV (PRQR) with a buy rating and an $8 price target, validating its Axiomer RNA-editing platform. Despite its early development stage, unprofitability, and negative cash flow, the stock is considered moderately undervalued by GuruFocus's GF …

ProQR a new buy at BoA on RNA-editing platform

[bad day at wall street] franckreporter * Bank of America Securities has initiated coverage of ProQR Therapeutics (PRQR [https://seekingalpha.com/symbol/PRQR]) at buy, saying that the company's Axiomer RNA-editing platform has been validated, supporting its pipeline. * The bank has an $8 price target (~260% return …

BofA Securities initiates ProQR stock with buy on liver therapy

BofA Securities initiated coverage on ProQR Therapeutics (NASDAQ:PRQR) with a buy rating and an $8.00 price target, citing the potential of its liver therapy AX-0810, which targets NTCP. The therapy aims to address biliary atresia, a childhood liver disease with no approved disease-modifying treatment. …

ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America

Bank of America has initiated coverage on ProQR Therapeutics (NASDAQ:PRQR) with a "buy" rating and an $8.00 price target, suggesting a significant upside. This positive outlook is supported by recent strong quarterly earnings, where ProQR exceeded revenue and EPS expectations, and substantial insider stock …

Equities Analysts Set Expectations for PRQR FY2030 Earnings

HC Wainwright has updated its FY2030 earnings per share estimate for ProQR Therapeutics (NASDAQ:PRQR) to $0.20, an increase from $0.18, and reiterated a "Buy" rating. Despite this positive revision, the consensus full-year earnings estimate remains a loss of $0.52 per share. The biopharmaceutical company …

H.C. Wainwright reiterates ProQR stock rating on platform data

H.C. Wainwright has reiterated its Buy rating and $12.00 price target for ProQR Therapeutics (NASDAQ:PRQR), citing strong platform data, particularly for AX-0810, which showed promising target engagement and an eight-week half-life in a Phase 1 study. The firm believes AX-0810's differentiated mechanism could address …

ProQR Therapeutics (PRQR) Stock Rises On Revenue Surge As Losses Ease

ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results

ProQR: Q2 Earnings Snapshot